Dyne Therapeutics. has filed a patent for complexes and formulations targeting Duchenne Muscular Dystrophy. The invention involves phosphorodiamidate morpholino oligomer linked to an anti-TfR1 antibody, formulated with histidine and sucrose for treatment. GlobalData’s report on Dyne Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Dyne Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Dyne Therapeutics, Antibody-conjugate nanoparticles was a key innovation area identified from patents. Dyne Therapeutics's grant share as of January 2024 was 8%. Grant share is based on the ratio of number of grants to total number of patents.

Formulation for treating duchenne muscular dystrophy

Source: United States Patent and Trademark Office (USPTO). Credit: Dyne Therapeutics Inc

The patent application (Publication Number: US20240016950A1) describes a complex comprising a specific structure formula (I) involving covalently linked groups R1 and R2, where R1 includes a specific group formula and R2 consists of a Fab with defined heavy and light chain amino acid sequences. The complex is designed for promoting the expression or activity of dystrophin protein in a subject, particularly in cases of mutated DMD alleles associated with Duchenne Muscular Dystrophy. The method involves administering a composition containing the described complex to the subject, with potential applications in treating individuals with specific mutations amenable to exon 51 skipping.

The patent further details variations of the complex structure formula (I) with different group formulas for R1, each designed to promote dystrophin protein expression or activity in subjects with mutated DMD alleles. The methods outlined in the patent involve administering compositions containing these complexes to individuals with Duchenne Muscular Dystrophy-associated mutations, particularly those amenable to exon 51 skipping. The innovative approach aims to address the underlying genetic causes of the condition by targeting specific mutations and promoting the production of functional dystrophin protein, potentially offering a targeted treatment option for individuals with these genetic abnormalities.

To know more about GlobalData’s detailed insights on Dyne Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies